The growing role of multi-omics within drug discovery Harnessing multi-omics and AI, researchers are transforming drug discovery by revealing disease mechanisms, pinpointing therapeutic targets, and speeding up development. Written byBree Foster, PhD

The growing role of multi-omics within drug discovery Harnessing multi-omics and AI, researchers are transforming drug discovery by revealing disease mechanisms, pinpointing therapeutic targets, and speeding up development. Written byBree Foster, PhD https://www.drugdiscoverynews.com/the-growing-role-of-multi-omics-within-drug-discovery-17097?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--eZkE2RFdsdMb8DN-kmWB7uVa8nUXSe_FENTgeLw6eyAzhg2Iv9oKOCJcXyI-8gDfb-AfL_hKpZGbeNQRdhcBe6WJn0A&_hsmi=434032591&utm_content=434032591&utm_source=hs_email Drug discovery has long been a high-risk, high-reward endeavor. Developing a new therapeutic from initial concept to market approval can take over a decade and cost more than $2 billion on average. Despite these staggering investments, the failure rate remains high, with many drugs faltering in late-stage clinical trials due to unforeseen toxicity, lack of efficacy, or poor patient stratification. Traditional approaches often focus on targeting a single molecule or pathway, an approach increasingly recognized as insufficient for tackling complex diseases such as cancer, neurodegeneration, and autoimmune disorders. Can better training data fix AI antibody design? The field has invested heavily in building better models for antibody discovery. The structural interaction data those models are trained on has not kept pace — and that shortfall is now a defining constraint on what AI can reliably do. Written byAndrea Corona https://www.drugdiscoverynews.com/can-better-training-data-fix-ai-antibody-design-17211?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9IHi0YXjvamui5CmnXpL0g-NVgV9akzvA8Ls0j41AjlkP-O-L47wYGyJc68CPWAD6TcLZFCq8ES_RyJ048aEny6RQKcg&_hsmi=434032591&utm_content=434032591&utm_source=hs_email The last several years of progress in protein artificial intelligence (AI) have been undeniably impactful. AlphaFold's demonstration that protein folding could be predicted with near-experimental accuracy reset expectations across structural biology, and the models that followed, for protein design, interaction prediction, and sequence generation, have moved antibody discovery into a new computational era.

AI-based analysis offers new roadmap for precision oncology The new approach combined digital pathology with spatial proteomics to uncover the secrets of metastasis and personalized treatment options. Written byAllison Whitten, PhD

AI-based analysis offers new roadmap for precision oncology The new approach combined digital pathology with spatial proteomics to uncover the secrets of metastasis and personalized treatment options. Written byAllison Whitten, PhD https://www.drugdiscoverynews.com/ai-based-analysis-offers-new-roadmap-for-precision-oncology-17460 How and why a tumor metastasizes — when a seemingly similar tumor doesn’t — remains one of the biggest questions in cancer research. New research from György Marko-Varga’s lab at Lund University with Istvan Nemeth at the Szeged Clinical hospital, and Peter Horvath’s team at HUN-REN Biological Research Centre suggests a new way to chip away at this question with the help of AI combined with spatial proteomics to reveal the single-cell dynamics of different populations of cancer cells within the same tumor. Their approach offers a promising step up over traditional molecular analyses that view the entire tissue sample at once and miss the functional differences in how different cell types behave.

As Healthy As Possible A Non-Profit Focused On POLR2A

https://ashealthyaspossible.net/ As Healthy as Possible As Healthy as Possible, which works to make research benefiting people with a POLR2A gene mutation more accessible and visible, has released a new newsletter. It shares one family’s journey to diagnosis and highlights the POLR2A Patient Registry, which explores how different mutations relate to symptoms and disease severity. People with a POLR2A genetic testing report can contribute by completing the available surveys. https://download2.eurordis.org/As_Healthy_As_Possible_Newsletter_June.pdf

What are Lysosomal Storage Diseases? + + + +

Following a general animation on Lysosomal Storage Diseases, the Platt Lab, in collaboration with patient associations, has created new animations on Niemann-Pick Diseases and GM2 gangliosidoses. Available in several languages, they explain each condition, diagnosis and treatment options, and signpost sources of patient and mental health support. Watch the animation on Niemann-Pick Diseases and the animation on GM2 gangliosidoses. https://plattlab.nsms.ox.ac.uk/ What are Niemann-Pick Diseases? What are the GM2 gangliosidoses: Tay-Sachs and Sandhoff disease?

ERDERA has launched its Clinical Trial Call (ECTC) to support multinational, GCP‑compliant early‑phase interventional clinical trials in rare diseases.

https://erdera.org/call/ctc2026/ ERDERA (the European Rare Diseases Research Alliance) has launched a Clinical Trial Call to support multinational, GCP-compliant Phase I, Phase I/II and Phase II interventional trials in rare diseases. Funding aims to generate robust, regulatory-relevant clinical evidence, with priority given to paediatric and rapidly progressive rare diseases, and those with no approved treatment options. Applications are open to research institutes, clinical centres, NGOs, patient advocacy organisations and SMEs. The deadline is 10 September.

Raising awareness on managing competing interests in a multi-stakeholder environment: Guidance to patients and engaging stakeholders + + +

https://imi-paradigm.eu/PEtoolbox/conflict-of-interest/ Conflict of Interest Interested in learning how to manage competing interests in a multi-stakeholder environment? The EURORDIS Open Academy is offering a course providing guidance to patients on best practices for multi-stakeholder interactions. Based on a guide from PARADIGM, this course explores how to avoid and minimise conflict of interest by suggesting risk mitigation strategies. https://openacademy.eurordis.org/ Conflict of interest in patient engagement https://openacademy.eurordis.org/courses/conflict-of-interest-in-patient-engagement/

The JARDIN Hackathon to Seek Solutions to Overcome Technical Barriers in Health Data Exchange: From the Point of Care to European Registry Networks

https://datascience.codata.org/articles/10.5334/dsj-2026-029 This article describes the methods and outcomes of a JARDIN hackathon exploring technical barriers to secure health data exchange between healthcare providers, national registries and ERNs. The authors, including Veronica Popa, our Digital Patient Engagement Manager, present potential solutions to improve the exchange and interoperability of rare disease data.